Faisal Khurshid
Stock Analyst at Leerink Partners
(4.43)
# 284
Out of 5,180 analysts
41
Total ratings
44.83%
Success rate
46.09%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Downgrades: Hold | $91 → $76 | $66.04 | +15.09% | 1 | Mar 30, 2026 | |
| VSTM Verastem | Assumes: Buy | $19 → $15 | $4.96 | +202.42% | 1 | Mar 30, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $107 → $110 | $101.57 | +8.30% | 2 | Mar 19, 2026 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $122 → $110 | $79.45 | +38.45% | 4 | Mar 16, 2026 | |
| INSM Insmed | Assumes: Buy | $228 | $152.82 | +49.20% | 1 | Mar 16, 2026 | |
| COGT Cogent Biosciences | Assumes: Buy | $55 | $35.88 | +53.29% | 1 | Mar 16, 2026 | |
| DSGN Design Therapeutics | Initiates: Buy | $15 | $10.51 | +42.72% | 1 | Mar 16, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiates: Buy | $160 | $101.30 | +57.95% | 1 | Mar 16, 2026 | |
| ONC BeOne Medicines AG | Downgrades: Hold | $420 → $290 | $284.41 | +1.97% | 1 | Mar 16, 2026 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Hold | $522 → $330 | $317.70 | +3.87% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 → $94 | $91.22 | +3.05% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $16 | $11.43 | +39.98% | 2 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $4 | $3.30 | +21.21% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $29 → $40 | $29.08 | +37.55% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $12.94 | +54.56% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $0.74 | +34.43% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $2 | $6.07 | -67.05% | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $88 → $102 | $76.83 | +32.76% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3 → $1 | $3.24 | -69.14% | 2 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $46.44 | -3.09% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $16 | $14.51 | +10.27% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.18 | +69.49% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $73.86 | +8.31% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $5.67 | +164.55% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $14.65 | +207.17% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.40 | +400.00% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.40 | +233.33% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $1.08 | +365.12% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | - | - | 1 | Mar 21, 2023 |
PTC Therapeutics
Mar 30, 2026
Downgrades: Hold
Price Target: $91 → $76
Current: $66.04
Upside: +15.09%
Verastem
Mar 30, 2026
Assumes: Buy
Price Target: $19 → $15
Current: $4.96
Upside: +202.42%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Outperform
Price Target: $107 → $110
Current: $101.57
Upside: +8.30%
Kymera Therapeutics
Mar 16, 2026
Assumes: Buy
Price Target: $122 → $110
Current: $79.45
Upside: +38.45%
Insmed
Mar 16, 2026
Assumes: Buy
Price Target: $228
Current: $152.82
Upside: +49.20%
Cogent Biosciences
Mar 16, 2026
Assumes: Buy
Price Target: $55
Current: $35.88
Upside: +53.29%
Design Therapeutics
Mar 16, 2026
Initiates: Buy
Price Target: $15
Current: $10.51
Upside: +42.72%
ABIVAX Société Anonyme
Mar 16, 2026
Initiates: Buy
Price Target: $160
Current: $101.30
Upside: +57.95%
BeOne Medicines AG
Mar 16, 2026
Downgrades: Hold
Price Target: $420 → $290
Current: $284.41
Upside: +1.97%
Alnylam Pharmaceuticals
Mar 16, 2026
Downgrades: Hold
Price Target: $522 → $330
Current: $317.70
Upside: +3.87%
Mar 16, 2026
Downgrades: Hold
Price Target: $120 → $94
Current: $91.22
Upside: +3.05%
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $11.43
Upside: +39.98%
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $3.30
Upside: +21.21%
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $29.08
Upside: +37.55%
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $12.94
Upside: +54.56%
Sep 15, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.74
Upside: +34.43%
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $6.07
Upside: -67.05%
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $76.83
Upside: +32.76%
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $3.24
Upside: -69.14%
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $46.44
Upside: -3.09%
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $14.51
Upside: +10.27%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.18
Upside: +69.49%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $73.86
Upside: +8.31%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $5.67
Upside: +164.55%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $14.65
Upside: +207.17%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.40
Upside: +400.00%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $2.40
Upside: +233.33%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $1.08
Upside: +365.12%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: -
Upside: -